Another randomized study conducted in 30 patients with early stages of chronic hepatitis C in Japan showed that oral losartan and UDCA administration has the potential to reduce serum type IV collagen and TGF-β1 compared to UDCA alone, but not liver fibrosis as indicated by METAVIR fibrosis score [58]. This evidence concerns the gene TGFB1 and Hepatic fibrosis.